Myobloc® (rimabotulinumtoxinB)

Myobloc (rimabotulinumtoxinB) is covered for adults (≥18 years) for FDA‑approved cervical dystonia and chronic sialorrhea and for an approved off‑label compendial use in upper limb spasticity. Approvals are for 12 months, require a diagnosis that meets coverage criteria, specify dosing (cervical dystonia 2,500–5,000 units divided among affected muscles; chronic sialorrhea 1,500–3,500 units divided among parotid/submandibular glands; upper limb spasticity 10,000 units) and a frequency limit of no more often than every 12 weeks, with no specific prior‑authorization documentation checklist specified.

"Treatment of cervical dystonia in adults (FDA-approved indication)"

Sign up to see full coverage criteria, indications, and limitations.